A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Public ClinicalTrials.gov record NCT05578976. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in groups called treatment arms. Participants will receive epcoritamab combined with R-CHOP, followed by epcoritamab or R-CHOP followed by rituximab will be explored. Approximately 900 adult participants with with newly diagnosed DLBCL will be enrolled in the study in approximately 315 sites in globally. In the Arm 1, participants will receive subcutaneous epcoritamab combined with intravenous and oral R-CHOP followed by subcutaneous epcoritamab in 21-day cycles. In the Arm 2, participants will receive intravenous and oral R-CHOP followed by intravenous rituximab in 21-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Study identification
- NCT ID
- NCT05578976
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 900 participants
Conditions and interventions
Conditions
Interventions
- Epcoritamab Drug
- Cyclophosphamide Drug
- Rituximab Drug
- Vincristine Drug
- Doxorubicin Drug
- Prednisone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 8, 2023 (Actual)
- Primary completion
- Jun 2027 (Estimated)
- Completion
- Dec 2029 (Estimated)
- Last update posted
- Sep 11, 2026
2023 – 2029
United States locations
- U.S. sites
- 68
- U.S. states
- 29
- U.S. cities
- 60
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Duplicate_University of Arizona Cancer Center - North Campus /ID# 227463 | Tucson | Arizona | 85719-1478 | — |
| Yuma Regional Medical Center Cancer Center /ID# 261527 | Yuma | Arizona | 85364 | — |
| University of Arkansas for Medical Sciences /ID# 225703 | Little Rock | Arkansas | 72205 | — |
| CBCC Global Research, Inc. /ID# 262037 | Bakersfield | California | 93309 | — |
| Alta Bates Summit Medical Center for Research /ID# 229427 | Berkeley | California | 94705 | — |
| Orange Coast Memorial Medical Center /ID# 229632 | Fountain Valley | California | 92708 | — |
| Providence - St. Jude Medical Center /ID# 262042 | Fullerton | California | 92835 | — |
| Saddleback Memorial Medical Center /ID# 229631 | Laguna Hills | California | 92653-3689 | — |
| Long Beach Memorial Medical Ct /ID# 228996 | Long Beach | California | 90806-1701 | — |
| Cancer and Blood Speciality Clinic - Los Alamitos /ID# 262032 | Los Alamitos | California | 90720-3309 | — |
| University of Southern California /ID# 225443 | Los Angeles | California | 90033 | — |
| University of California, Los Angeles /ID# 226887 | Los Angeles | California | 90095 | — |
| Kaiser Permanente, Waterpark III Institute for Health Research /ID# 228618 | Aurora | Colorado | 80014 | — |
| Duplicate_Cancer Specialists of North Florida /ID# 226826 | Jacksonville | Florida | 32256 | — |
| Ocala Oncology Florida Cancer Affiliates - Main /ID# 262785 | Ocala | Florida | 34474-4445 | — |
| Orlando Health Cancer Institute /ID# 232626 | Orlando | Florida | 32806 | — |
| Straub Medical Center /ID# 229464 | Honolulu | Hawaii | 96813-3097 | — |
| University of Illinois at Chicago /ID# 226889 | Chicago | Illinois | 60607 | — |
| Southern IL Univ School of Med /ID# 228999 | Springfield | Illinois | 62702 | — |
| Springfield Clinic Main Campus /ID# 262584 | Springfield | Illinois | 62703-2403 | — |
| Carle Cancer Institute /ID# 228338 | Urbana | Illinois | 61801-1645 | — |
| Parkview Comprehensive Cancer Center /ID# 227026 | Fort Wayne | Indiana | 46845 | — |
| Goshen Center for Cancer Care /ID# 225534 | Goshen | Indiana | 46526 | — |
| University of Iowa Health Care /ID# 261945 | Des Moines | Iowa | 50314-3017 | — |
| Cancer Center of Kansas /ID# 261983 | Wichita | Kansas | 67214 | — |
| Norton Cancer Institute - St. Matthews /ID# 225420 | Louisville | Kentucky | 40207 | — |
| University of Maryland, Baltimore /ID# 225421 | Baltimore | Maryland | 21201 | — |
| Johns Hopkins Hospital /ID# 225369 | Baltimore | Maryland | 21287 | — |
| American Oncology Partners of Maryland /ID# 226859 | Bethesda | Maryland | 20817 | — |
| UMass Memorial Medical Center /ID# 226939 | Worcester | Massachusetts | 01605 | — |
| University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 225462 | Ann Arbor | Michigan | 48109 | — |
| Trinity Health St. Joseph Mercy Ann Arbor /ID# 228206 | Ypsilanti | Michigan | 48197-1051 | — |
| Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 226680 | Saint Louis Park | Minnesota | 55416 | — |
| University of Mississippi Medical Center /ID# 228045 | Jackson | Mississippi | 39216-4500 | — |
| Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 259014 | Billings | Montana | 59102 | — |
| NHO Revive Research Institute, LLC /ID# 261113 | Lincoln | Nebraska | 68506 | — |
| MDACC Cooper /ID# 260320 | Camden | New Jersey | 08103-1461 | — |
| Titan Health Partners LLC, d/b/a Astera Cancer Care /ID# 226654 | East Brunswick | New Jersey | 08816 | — |
| Morristown Medical Center /ID# 239457 | Morristown | New Jersey | 07960-6136 | — |
| University of New Mexico /ID# 227332 | Albuquerque | New Mexico | 87102-4517 | — |
| Presbyterian Kaseman Hospital /ID# 262084 | Albuquerque | New Mexico | 87110 | — |
| Presbyterian Rust Medical Center /ID# 262068 | Rio Rancho | New Mexico | 87124 | — |
| Roswell Park Cancer Institute /ID# 239127 | Buffalo | New York | 14263 | — |
| NYU Langone Hospital - Long Island /ID# 262412 | Mineola | New York | 11501 | — |
| New York Cancer and Blood Specialists- New Hyde Park /ID# 265392 | New Hyde Park | New York | 11042 | — |
| NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 226141 | New York | New York | 10016-4744 | — |
| New York Cancer and Blood Specialists- Manhattan /ID# 265391 | New York | New York | 10028 | — |
| Icahn School of Medicine at Mount Sinai /ID# 225370 | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center-Koch Center /ID# 225379 | New York | New York | 10065-6007 | — |
| New York Cancer and Blood Specialists /ID# 261114 | Port Jefferson Station | New York | 11776-8060 | — |
| New York Cancer and Blood Specialists- Eastchester, Bronx /ID# 265396 | The Bronx | New York | 10469 | — |
| Novant Health Presbyterian Medical Center /ID# 227753 | Charlotte | North Carolina | 28204 | — |
| East Carolina University - Brody School of Medicine /ID# 225992 | Greenville | North Carolina | 27834 | — |
| Novant Health Forsyth Medical Center /ID# 228339 | Winston-Salem | North Carolina | 27103 | — |
| University of Cincinnati /ID# 225374 | Cincinnati | Ohio | 45267 | — |
| OhioHealth Arthur G.H. Bing, MD Cancer Center /ID# 260790 | Columbus | Ohio | 43214-3908 | — |
| University of Oklahoma, Stephenson Cancer Center /ID# 225556 | Oklahoma City | Oklahoma | 73104-5418 | — |
| Kaiser Permanente - Northwest /ID# 225488 | Portland | Oregon | 97227 | — |
| Houston Methodist Hospital /ID# 258957 | Houston | Texas | 77030 | — |
| Millennium Research & Clinical Development /ID# 228284 | Kingwood | Texas | 77339-6008 | — |
| Joe Arrington Cancer Research /ID# 227217 | Lubbock | Texas | 79410 | — |
| Baylor Scott & White Medical Center- Temple /ID# 225935 | Temple | Texas | 76508-0001 | — |
| Intermountain Medical Center /ID# 231184 | Murray | Utah | 84107-5701 | — |
| University of Virginia Cancer Center - West Complex /ID# 225433 | Charlottesville | Virginia | 22903-3363 | — |
| Virginia Commonwealth University Medical Center Main Hospital /ID# 225796 | Richmond | Virginia | 23219 | — |
| Vista Oncology - East Olympia /ID# 229375 | Olympia | Washington | 98506-5028 | — |
| MultiCare Institute for Research & Innovation /ID# 225432 | Tacoma | Washington | 98405 | — |
| MultiCare Regional Cancer Center - Tacoma /ID# 265285 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 263 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05578976, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05578976 live on ClinicalTrials.gov.